PersonGen BioTherapeutics
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech company developing next-generation CAR-T and allogeneic cellular therapies for T-cell cancers and autoimmune diseases.
OncologyImmunology
Technology Platform
Multiple proprietary platforms including CD7-CAR-T for T-cell malignancies, GUIDED® for in vivo CAR-T/NK generation, MNano NE® for autoimmune bispecific antibodies, and eUCAR-gdT® for allogeneic γδT cell therapies.
Opportunities
Significant growth potential in the underserved T-cell malignancy market and autoimmune disease space, with their in vivo CAR-T platform potentially revolutionizing cell therapy accessibility and scalability.
Risk Factors
Clinical development risks for novel CAR-T approaches, regulatory hurdles in multiple jurisdictions, and intense competition in the rapidly evolving cell therapy landscape.
Competitive Landscape
Competes with autologous CAR-T leaders (Novartis, Gilead) and allogeneic CAR-T companies (Allogene, Cellectis), differentiated by specialized focus on T-cell malignancies and dual ex vivo/in vivo CAR-T platforms.